Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study

Michael R. Rickels, Katrina J. Ruedy, Nicole C. Foster, Claude A. Piché, Helene Dulude, Jennifer L. Sherr, William V. Tamborlane, Kathleen E. Bethin, Linda A. DiMeglio, R. Paul Wadwa, Andrew J. Ahmann, Michael J. Haller, Brandon M. Nathan, Santica M. Marcovina, Emmanouil Rampakakis, Linyan Meng, Roy W. Beck

Research output: Contribution to journalLetterpeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)e193-e194
JournalDiabetes care
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2016

Bibliographical note

Funding Information:
This work was funded by a grant from the Leona M. and Harry B. Helmsley Charitable Trust; by the National Center for Research Resourcesand theNationalCenter forAdvancing Translational Sciences, National Institutes of Health, throughgrantsUL1TR000003 (University of Pennsylvania), UL1TR000064 (University of Florida), and UL1TR001108 (Indiana University); and by Locemia Solutions ULC. Studies at the Barbara Davis Center for Childhood Diabetes were performed in their infusion center and not the hospital Clinical Translational Research Center. Locemia Solutions provided the intranasal glucagon product.

Cite this